$AVAH

Raymond James Names Top Healthcare Stocks for August

Raymond James updated its August healthcare top picks, adding Aveanna Healthcare (AVAH) ahead of its Aug. 13 earnings, and Carriage Services (CSV) after a ~20% decline since April, citing stabilizing funeral trends and valuation around 8x 2027 estimated EBITDA. It also added Viking Therapeutics (VKTX) for upcoming clinical readouts.

Original reporting
Published Aug 6, 2026, 1:46 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 1:57 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefSector analysis
Primary signal
$AVAH
Bullish
medium confidence
Mentioned
$AVAH · $CSV · $VKTX
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AVAHBullishLow
01

Why it matters

This is primarily a catalyst calendar and sentiment update. It may influence short-term positioning, but it does not introduce new financial guidance or newly released clinical outcomes in the text.

02

Market read

Traders may use the article as a timing reference for upcoming earnings/readouts, but it is not a primary disclosure of new results.

03

What to watch

Key risk is that the article provides expectations (upcoming catalysts) rather than results; traders should wait for the actual earnings/clinical readouts to confirm the thesis.

Relevance 4/10Novelty 3/10Timing: into upcoming earnings/readout windows referenced by the analyst list (Aug. 13 for AVAH; later this year for VKTX)

Background

Raymond James updated its monthly healthcare top picks, replacing one name on the list and adding two others based on upcoming earnings dates and expected clinical catalysts.

Company-level read

Ticker impact

$AVAHBullishMedium confidence
Context

Raymond James added Aveanna Healthcare to its healthcare top picks ahead of its Aug. 13 earnings report, citing near-term upside catalysts.

Expected impact

Likely modest, short-term sentiment support into the Aug. 13 earnings window; follow-through depends on the actual print.

Evidence & confidence

The article provides a specific timing catalyst (Aug. 13 earnings) and a stated thesis (rate increase discussion), but no new company financials or guidance.

$CSVBullishMedium confidence
Context

Raymond James added Carriage Services to top picks, pointing to stabilizing funeral trends and a valuation discount versus Service Corp.

Expected impact

Potential for incremental buying interest, but magnitude likely limited without a new earnings/guidance datapoint in the text.

Evidence & confidence

The article cites CDC-consistent trends and a peer multiple comparison, plus a stated ~20% decline since April, but does not disclose new company-specific results or guidance.

$VKTXBullishMedium confidence
Context

Raymond James added Viking Therapeutics to top picks, citing upcoming catalysts including initial readouts for VK2735 and VK3019.

Expected impact

Moderate upside bias into the expected readout windows later this year; price reaction will hinge on actual data.

Evidence & confidence

The text names specific pipeline programs and expected readout types, but it is framed as outlook rather than newly reported clinical outcomes.

Market effects

Reinforces a near-term bullish bias in healthcare names with identifiable catalysts (earnings or clinical readouts), but does not change sector fundamentals.

No specific regional policy or macro shock tied to the named stocks.

Limited, as the catalysts are company-specific and the piece is an analyst monthly list update.

Counterpoint

Analyst “top picks” updates can be largely promotional and may not translate into sustained performance without new earnings, guidance, or trial data.

Key entities

  • Raymond James

    Updated its monthly healthcare sector top picks with three named companies and stated catalyst rationales.

  • Aveanna Healthcare

    Added to the top picks ahead of Aug. 13 earnings, with a thesis tied to near-term sentiment drivers.

  • Carriage Services

    Added to the top picks based on stabilizing funeral trends and a valuation discount versus a peer.

  • Viking Therapeutics

    Added to the top picks based on expected near-term clinical readouts for VK2735 and VK3019.

Related articles

$VKTXLowAI 8/10

Viking Therapeutics Initiates Pivotal Phase 3 Trial: Here's Why Investors Have Reason for Optimism After a Disappointing Phase 2

Viking Therapeutics (VKTX) has initiated two Phase 3 trials for its oral weight loss drug, VK2735, targeting obesity and type 2 diabetes. The move follows mixed Phase 2 results, with concerns about tolerability. The company aims to improve outcomes with a longer trial duration, reduced tablet size, and lower dosing. Phase 1 data showed good tolerability, but Phase 2 had a 20% discontinuation rate due to adverse events.

$VKTXMed

Viking Launches Phase 3 SUNRISE Program For Oral Obesity Drug VK2735

Viking Therapeutics (VKTX) began Phase 3 trials for its obesity drug VK2735, testing oral formulations in two 68-week studies with 560 adults each. The trials aim to assess efficacy and safety, with primary endpoints measuring weight change. VK2735 previously showed promising results in a Phase 2 study. The company reported $502M in cash reserves as of June 30, 2026, with its stock trading between $25.77 and $43.15 over the past year.

$VKTXMedAI 8/10

Viking’s Key Obesity Pill Enters Phase 3 Trial – Here’s What Investors Need To Know

Viking Therapeutics (VKTX) has begun Phase 3 trials for its obesity pill, VK2735, competing with Eli Lilly (LLY) and Novo Nordisk (NVO). The company aims to offer both oral and injectable treatments, but regulatory approval depends on trial success. VKTX shares are down 24% this year, underperforming LLY but outperforming NVO. Retail sentiment on Stocktwits is bearish.

$VKTXMed

Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3

Viking Therapeutics (VKTX) has started Phase 3 trials for its oral obesity drug VK2735, targeting adults with and without type 2 diabetes. The SUNRISE-1 and SUNRISE-2 studies will evaluate the drug's efficacy and safety over 68 weeks, with primary endpoints measuring body weight change. Viking aims to expand treatment options for obesity with this once-daily oral therapy, complementing its subcutaneous formulation in Phase 3 trials.